16 December 2009 in BMC Medical Genetics
Background: Several studies have reported the association of the SNP rs2414096 in the CYP19 gene with hyperandrogenism, which is one of the clinical manifestations of polycystic ovary syndrome (PCOS). These studies suggest that SNP rs2414096 may be involved in the etiopathogenisis of PCOS. To investigate whetherthe CYP19 gene SNP rs2414096 polymorphism is associated with the susceptibility to PCOS, we designed a case-controlled association study including 684 individuals. Methods: A case-controlled association study including 684 individuals (386 PCOS patients and 298 controls) was performed to assess the association of SNP rs2414096 with PCOS. Genotyping of SNP rs2414096 was conducted by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method that was performed on genomic DNA isolated from blood leucocytes. Results were analyzed in respect to clinical test results. Results: The genotypic distributions of rs2414096 (GG, AG, AA) in the CYP19 gene (GG, AG, AA) in women with PCOS (0.363, 0.474, 0.163, respectively) were significantly different from that in controls (0.242, 0.500, 0.258, respectively) (P = 0.001). E2/T was different between the AA and GG genotypes. Age at menarche (AAM) and FSH were also significantly different among the GG, AG, and AA genotypes in women with PCOS (P = 0.0391 and 0.0118, respectively). No differences were observed in body mass index (BMI) and other serum hormone concentrations among the three genotypes, either in the PCOS patients or controls. Conclusions: Our data suggest that SNP rs2414096 in the CYP19 gene is associated with susceptibility to PCOS.
14 July 2009 in BMC Medical Genetics
Background: I/D polymorphisms of ACE are associated with the plasma ACE concentration. The ACE is associated with the angiogenesis of ovarian endothelium in vitro as well as steroidogenesis and follicular growth in cattle. Since ACE induces a high blood supply and hypersteroidogenesis in the ovary, it may be associated with polycystic ovary syndrome (PCOS) which exhibits hyperplasia, hypervascularity of the ovarian theca interna and stroma, as well as disorderd steroidogenesis. Therefore, we hypothesized that the ACE plays some roles in the human ovary. To investigate whether the ACE I/D polymorphisms are associated with the steroidogenesis disorder in PCOS and contribute to the susceptibility of PCOS in Chinese women, we designed a case-controlled association study in 582 individuals. Methods: The ACE I/D polymorphisms were assessed in 582 reproductive-age women. Genotyping and frequency of ACE I/D polymorphisms were obtained by PCR amplification that was performed on genomic DNA isolated from blood leucocytes. Results were analyzed in respect to clinical test results. Results: The frequencies of the D allele and the genotypic distributions (DD, ID and II) in the women with PCOS did not differ from those in controls (P = 0.458). However, there were significant differences in the concentrations of testosterone among three genotypes both in the PCOS patients and controls (P = 0.0045, P = 0.0052, respectively). Differences were also found between these groups with distinct genotypes: DD versus II and DI versus II in the PCOS patients as well as DD versus DI and DD versus II in the controls. There were significant differences in the ratio of LH/FSH among three genotypes in the patients (P = 0.01). However, there were no statistical differences in the BMI, AAM, E2 concentrations and other serum hormone concentrations among the three genotypes both in the PCOS patients and controls. Conclusion: The ACE I/D polymorphisms were not associated with the pathogenesis of PCOS. However, the polymorphisms were associated with the steroidogenesis in the ovary. The observation indicated that the ACE I/D polymorphisms were not the key etiological factor, which in stead may be associated with the aggravated clinical manifestations of PCOS.
7 February 2020 in medRxiv
Background and Purpose: Limited optimization was clinically applicable for reducing missed diagnosis, misdiagnosis and inter-reader variability in pulmonary nodule diagnosis. We aimed to propose a deep learning-based algorithm and a practical strategy to better stratify the risk of pulmonary nodules, thus reducing medical errors and optimizing the clinical workflow. Materials and Methods: A total of 2,348 pulmonary nodules (1,215 with lung cancer) containing screened nodules from National Lung Cancer Screening Trial (NLST) and incidentally detected nodules from Jinling Hospital (JLH) were used to train and evaluate a deep learning algorithm, Filter-guided pyramid network (FGP-NET). Internal and external test of FGP-NET were performed on two independent datasets (n=542). The performance of FGP-NET at Youden point which maximizing the Youden index was compared with 126 board-certificated radiologists. We further proposed Hierarchical Ordered Network ORiented Strategy (HONORS), which manipulates the emphasis either on sensitivity or specificity to target risk-stratified clinical scenarios, directly making decisions for some patients. Results: FGP-NET achieved a high area under the curve (AUC) of 0.969 and 0.855 for internal and external testing, and was comparable or even outperformed the radiologists when considering sensitivity. HONORS-guided FGP-NET identified benign nodules with a high sensitivity (95.5%) in the screening scenario, and demonstrated satisfactory performance for the rest ambiguous nodules with 0.945 of AUC by the Youden point. FGP-NET also detected lung cancer with a high specificity of 94.5% in routine diagnostic scenario; an AUC of 0.809 was achieved for the rest nodules. Conclusion: The combination of HONORS and FGP-NET provides well-organized stratification for pulmonary nodules and also offers the potential for reducing medical errors. Highlights: Pulmonary nodules were managed for both screening and diagnostic scenarios Proposal of a hierarchical strategy for targeting risk-stratified clinical scenarios A large scale Human-deep learning contest for reliable performance evaluation
26 August 2026 in Neuroradiology